TY - JOUR
T1 - Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis
T2 - A retrospective study from daily clinical practice
AU - Sharif, Kassem
AU - Gendelman, Omer
AU - Langevitz, Pnina
AU - Reitblat, Tatiana
AU - Watad, Abdulla
AU - Shoenfeld, Yehuda
AU - Azuri, Josef
AU - Amital, Howard
AU - Bragazzi, Nicola Luigi
AU - Shovman, Ora
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Golimumab is a recombinant human monoclonal antibody targeted against tumour necrosis factor-alpha (TNF-α). Golimumab is effective in the management of patients with active psoriatic arthritis (PsA). The aim of this study is to evaluate the clinical efficacy and survival of golimumab monotherapy versus co-administration with methotrexate (MTX) in patients with PsA in the clinical practice. This retrospective observational trial included patients with PsA. Efficacy was assessed by disease activity scores – DAS28, BASDAI, physician global assessment of disease (PGA) and CRP. Golimumab survival rate was estimated using the Kaplan-Meier analysis and univariate and multivariate Cox regression models. Forty-one patients with PsA were recruited; 26 patients were treated with golimumab, whereas 15 patients received combination therapy with MTX. The treatment resulted in significantly improved clinical measures of disease activity in comparison with baseline, including DAS28 CRP (4.1 vs 2.6, p ≤ 0.0001) and BASDAI (5.6 vs 3.8, p ≤ 0.001). Overall, 29 (71%) patients continued golimumab treatment (18 patients on monotherapy and 11 on combination therapy). The difference in the duration of golimumab survival between the combination therapy and monotherapy groups was not statistically significant (12.5 vs 12 months, p = 0.2). Similar efficacy profiles and survival rates were documented in patients with PsA regardless of the co-administration of methotrexate.
AB - Golimumab is a recombinant human monoclonal antibody targeted against tumour necrosis factor-alpha (TNF-α). Golimumab is effective in the management of patients with active psoriatic arthritis (PsA). The aim of this study is to evaluate the clinical efficacy and survival of golimumab monotherapy versus co-administration with methotrexate (MTX) in patients with PsA in the clinical practice. This retrospective observational trial included patients with PsA. Efficacy was assessed by disease activity scores – DAS28, BASDAI, physician global assessment of disease (PGA) and CRP. Golimumab survival rate was estimated using the Kaplan-Meier analysis and univariate and multivariate Cox regression models. Forty-one patients with PsA were recruited; 26 patients were treated with golimumab, whereas 15 patients received combination therapy with MTX. The treatment resulted in significantly improved clinical measures of disease activity in comparison with baseline, including DAS28 CRP (4.1 vs 2.6, p ≤ 0.0001) and BASDAI (5.6 vs 3.8, p ≤ 0.001). Overall, 29 (71%) patients continued golimumab treatment (18 patients on monotherapy and 11 on combination therapy). The difference in the duration of golimumab survival between the combination therapy and monotherapy groups was not statistically significant (12.5 vs 12 months, p = 0.2). Similar efficacy profiles and survival rates were documented in patients with PsA regardless of the co-administration of methotrexate.
KW - Drug survival
KW - Efficacy
KW - Golimumab
KW - Methotrexate
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85062017227&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2019.02.012
DO - 10.1016/j.berh.2019.02.012
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85062017227
SN - 1521-6942
VL - 32
SP - 692
EP - 700
JO - Best Practice and Research: Clinical Rheumatology
JF - Best Practice and Research: Clinical Rheumatology
IS - 5
ER -